Collegium Pharmaceutical reported better-than-expected Q2 earnings, leading to stock price increase and upgraded ratings.
Collegium Pharmaceutical reported better-than-expected Q2 earnings, with EPS of $1.62 and revenue of $145.28M, up 7.2% YoY. Its stock price increased to $35.50 on the news. Analysts at Piper Sandler maintained a "neutral" rating on COLL, with a lowered price target of $37, while Jefferies Financial Group upgraded their rating to "buy" and HC Wainwright also upgraded to "buy" with a $47 price target. The company's market cap is $1.16B and has a consensus rating of "Moderate Buy" with an average target price of $42.
August 11, 2024
4 Articles